Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Year range
1.
Fisioter. mov ; 18(3): 55-64, jul.-set. 2005. tab
Article in Portuguese | LILACS | ID: lil-438526

ABSTRACT

Um dos equipamentos termoterapêuticos utilizados para a produção do calor é o que utiliza princípios de ultra-som (US) produzindo calor profundo pela propagação das suas ondas mecânicas, que são essencialmente as mesmas das ondas sonoras, mas com uma frequência mais alta. O US é produzido por uma corrente alternada que flui por um cristal piezoelétrico, alojado em um transdutor. Os efeitos do US dependem de muitos fatores físicos e biológicos, tais como a iontensidade, o tempo de exposição, a estrutura espacial e temporal do campo ultra-sônico e o estado fisiológico do local a ser tratado. Este grande número de variáveis complica a compreensão exata do seu mecanismo de ação na interação com os tecidos biológicos. Os efeitos do US vem sendo investigados e descritos de maneira empírica através dos tempos e as opinio~es sobre as dosagens utilizadas para o tratamento diferem significativamente, existindo poucas evidências dos seus efeitos clínicos. Sendo assim, este trabalho tem como objetivo apontar, mediante uma revisão bibliográfica, se existem parâmetros físicos e biológicos para determinaçãoi das doses de US, quando utilizado para fins terapêuticos


Subject(s)
Dosimetry , Hyperthermia, Induced , Ultrasonics
2.
GED gastroenterol. endosc. dig ; 19(2): 69-72, mar.-abr. 2000. tab
Article in English | LILACS | ID: lil-312484

ABSTRACT

Background: There is not yet consensus on the most effective treatment for the helicobacter pylori infection, particularly in most developing countries. Azithromycin is a new macrolide and relatively novel agent for H. pylori eradication with an in vitro MIC90 lower than 1 mg/ml.Secnidazole, a nitromidazole that causes fewer side effects than metronidazole, was recenty reported to be used, for the firt time, in the treatment of H. pylori infection. Aim: To evaluate, in a prospective, randomized, single-center study, the association of twodifferent doses of omeprazole, azithromycin and secnidazole in H. pylori eradication. Patients and methods: After informed consent, 55 patients (36m,19F) with duodenal ulcer associated with H. pylori infection were randomized to receive omeprazole 20mg uid (Group A) or 20mg bid (Group B) for sevem days plus azithromycin 500mg uid for six days and secnidazole 2,000mg uid in the first, fourth and seventh day. The H. pylori status was assessed before and 60-90 days posttreatment using urease test, histology and 13C-urea breath test. Statistical analysis was performed by X² test. Results: The two groups had similar demographic characteristics. Fifty-five patients (36M, 19F) were enrolled. Six patients did not show-up for the second visit posttreatment. So, of the 49 evaluable patients, 25por cento (6/24) in Group A and 44por cento(11/25) in Group B wereeradicated, in a per protocol (PP) analysis. Intetion-to-treat (ITT) eradication rates were 21,4por cento (6/28) in Group A and 40.7por cento (11/27) im Group B. The differences betweem ITT and PP analysis from the two groups were not statistically significant. Conclusions: This study shows a very low eradication rate with the two regimens comprising of omeprazole, azithromycin and secnidazole and therefore, should not be recommended for thetreatment of H. pylori infection


Subject(s)
Humans , Male , Female , Adult , Azithromycin , Helicobacter pylori , Omeprazole , Prospective Studies , Duodenal Ulcer/therapy , Clinical Trials as Topic
SELECTION OF CITATIONS
SEARCH DETAIL